companies / sur180therapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-08 json
| total_raised | 1,239,9871.2M | ○ |
|---|---|---|
| founded | null | |
| hq | Mcallen, Texas, USA | |
| industry | unknown | |
| stage | null |
SBIR Phase II award from Department of Health and Human Services (National Institutes of Health): Phase II- Repurposing CRH antagonists for the treatment of endometriosis
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-01-01 | grant | 1,239,9871.2M | null | ○ |
Google Cloud CDN, Sentry, Vercel Speed Insights, WebsiteBuilder, Wix, Google Cloud, React, lodash .
| fact | status | src |
|---|---|---|
| Grant, $1.2M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |